EDGAR Filing Documents for 0001193125-19-115862

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:

SEC Accession No. 0001193125-19-115862

Filing Date

2019-04-24

Accepted

2019-04-24 08:31:03

Documents

Effectiveness Date

2019-04-24

Document Format Files

Seq	Description	Document	Type	Size
1	DEFA14A	d738637ddefa14a.htm	DEFA14A	32017
2	GRAPHIC	g738637dsp002.jpg	GRAPHIC	1750
3	GRAPHIC	g738637dsp003.jpg	GRAPHIC	7619
4	GRAPHIC	g738637dsp003a.jpg	GRAPHIC	1762
5	GRAPHIC	g738637dsp004.jpg	GRAPHIC	1748
	Complete submission text file	0001193125-19-115862.txt		51345

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080

Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700

Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38693 | Film No.: 19762682
SIC: 2836 Biological Products, (No Diagnostic Substances)